Wanbury receives ESQM approval for new product Rivaroxaban API
Mumbai, Aug. 13 -- Wanbury received approval from the office of European Directorate for the Quality of Medicines and Healthcare (EDQM) for new product Rivaroxaban API. The approval paves way to meet customer demand of EU and other countries accepting CEP.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.